Welcome to our dedicated page for WaveDancer SEC filings (Ticker: WAVD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating cybersecurity revenue streams or dissecting zero-trust contract details inside WaveDancer’s bulky reports can drain hours. The company’s disclosures span intricate supply-chain risk narratives and dense technical jargon—exactly what makes WaveDancer SEC filings explained simply a persistent challenge for analysts.
Stock Titan solves that complexity. Our AI reads every WaveDancer quarterly earnings report 10-Q filing, annual report 10-K simplified, and 8-K material events explained the moment they hit EDGAR, then produces clear, plain-English summaries. Need WaveDancer insider trading Form 4 transactions? Real-time alerts surface WaveDancer Form 4 insider transactions real-time so you can monitor executive stock moves before markets react. Each document is paired with keyword search, red-flag highlights, and side-by-side comparisons, turning “understanding WaveDancer SEC documents with AI” from aspiration to reality.
Whether you’re tracking zero-trust contract wins, R&D outlays, or WaveDancer proxy statement executive compensation, our coverage makes the data actionable:
- AI-powered summaries for every section, from revenue concentration to cybersecurity risk factors
- Instant access to WaveDancer earnings report filing analysis across quarters
- Complete archive of WaveDancer executive stock transactions Form 4 with historical charts
Stop digging through PDFs. Follow all WaveDancer filings—from technical amendments to strategic 8-Ks—as they arrive, already distilled into the insights investors rely on.
Firefly Neuroscience, Inc. (WAVD) reported consolidated assets of $14,938 and cash of $5,918 at June 30, 2025, up from $4,601 and $1,810 at December 31, 2024. Revenue for the quarter was $299 and $342 for the six months, driven largely by the April 30, 2025 acquisition of Evoke Neuroscience, which contributed $251 of revenue and a $12 loss from April 30 to June 30. The company recorded a six-month net loss of $14,763 and an accumulated deficit of $106,257, resulting in basic and diluted loss per share of $1.69 for the six months. Shareholders' equity moved to $12,100 from a deficit of $(375) at year-end.
The acquisition cost totaled $6,221, producing $5,175 of goodwill and identifiable intangible assets including developed technology, trade name and non-compete agreements. Significant non-cash items materially affected results: a $9,369 change in derivative fair value and a $1,353 loss on settlement of a convertible promissory note. Operating cash used was $4,901 for six months while financing provided $11,388, primarily from equity issuances and warrant exercises. Management disclosed substantial doubt about the company’s ability to continue as a going concern but expects to seek additional capital.
WaveDancer, Inc. (CIK 0000803578) has filed a Form D on behalf of its subsidiary FIREFLY NEUROSCIENCE, INC. The filing notifies the SEC of a Rule 506(b) private placement of equity and related warrants/options. The total offering size is $2.0 million, of which $1.2 million (60%) has already been sold to two accredited investors since the first closing on 16-Jun-2025. $0.8 million remains available.
The offering is a new notice, is expected to last less than one year, and carries no minimum investment requirement. The issuer declined to disclose revenue or asset size and classifies itself under “Other Technology.” No sales commissions, finder’s fees, or payments to executive officers/directors are reported, suggesting the raise is being conducted directly by management in a cost-efficient manner.
Key executives named include CEO Greg Lipschitz, CFO Paul Krzywicki, and several board members. Proceeds are not earmarked for insider compensation, indicating funds are likely intended for operating or growth initiatives, although specific use is not disclosed in the form.
For investors, the filing signals (1) an additional capital infusion that may support product development in neuro-technology, (2) potential equity dilution depending on the terms of the securities issued, and (3) the company’s reliance on private accredited funding rather than public markets. Because the exemption used prohibits general solicitation, little further detail is available until subsequent disclosures or an S-1/8-K is filed.
FAQ
What is the current stock price of WaveDancer (WAVD)?
What is the market cap of WaveDancer (WAVD)?
